A method to treat conditions associated with A² peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human A² peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethylene glycol (PEG) molecule.
